| Literature DB >> 35698159 |
Qiong Wu1,2, Chanling Yuan1,2, Ningzhi Liu1,2, Jing Shu1,2, Jiacheng Wang1,2, Jiayi Qian1,2, Liang Zeng3, Hao Zhang4, Xicheng Wang5,6, Wenjie Mei7,8.
Abstract
BACKGROUND: Breast cancer targeting diagnostic agent with effective imaging ability is important in guiding plan formulation, prediction, and curative effect evaluation of tumors in clinic. A tumor-targeting nanoprobe based on the functional and programmable Liquid-Liquid phase separation of AS1411 promoted by Ru(II) complex RuPEP may develop into a potential phosphorescence probe to detect breast cancer cells, where AS1411 act as a tumor-targeting guidance moiety to distinguish tumor cells from normal cells and RuPEP act as a light-emitting element to highlight breast cancer cells.Entities:
Keywords: AS1411; Breast cancer; NCL; Tumor-targeting imaging
Mesh:
Substances:
Year: 2022 PMID: 35698159 PMCID: PMC9190138 DOI: 10.1186/s13046-022-02393-3
Source DB: PubMed Journal: J Exp Clin Cancer Res ISSN: 0392-9078
Scheme 1Schematic highlight the constructed nanoprobe of AS1411@RuPEP nanoparticles for precise breast cancer imaging of NCL targeting recognition
Fig. 1The nano-structure characterization of nanoprobe AS1411@RuPEP. A The binding properties of RuPEP interact with AS1411 by molecular docking analysis. B The elctronic absorption spectra and fluorescence emission spectra of RuPEP (5 μM) and AS1411@RuPEP (5 μM) in PBS solution. TEM image (C) and AFM image (D) of AS1411@RuPEP. The EDS analysis (E) and the EDS mapping (F) of elemental spectrum of AS1411@RuPEP. G Number-average diameters and particle size of AS1411@RuPEP in PBS, measured by DLS
Fig. 2Nanoprobe highlight tumor cells nucleus through ATP-dependent endocytosis. A Schematic illustration for the process of nanoprobe entered into nucleus by endocytosis. B The cellular localization of AS1411@RuPEP (5 µM) in MDA-MB-231 cells. The enlarge and 3D tomoscan image of the MDA-MB-231 nucleus in the presence of AS1411@RuPEP. The transport pathway of cellular uptake for complex AS1411@RuPEP in MDA-MB-231 cells. C Real-time imaging of the MDA-MB-231 cells treated with complex AS1411@RuPEP (5 μM) for 2 h. The cell morphology was captured using phosphorescence microscopy every 15 min. D Celluar uptake of AS1411@RuPEP (5 μM) was incubated in MDA-MB-231 cells labeled cell membrane in green fluorescence by DiO for 6 h at 37 °C and 4 °C; MDA-MB-231 cells cells were pre-treatment with Chlorpromazine (6 nM); Dexy (10 nM) + Olig (5 nM), CCCP (10 nM), respectively, then replacement of the inhibitors with AS1411@RuPEP (5 μM) was incubated in MDA-MB-231 cells for 6 h at 37 °C. E Bio-TEM imaging of MDA-MB-231 cells for cellular uptake of AS1411@RuPEP. Cells are treated with AS1411@RuPEP for 6 h at 37 °C
Fig. 3Tumor-selective imaging of NCL targeting recognition by AS1411@RuPEP nanoprobe. A The possible process of AS1411@RuPEP nanoprobe targeting recognize NCL on the cells membrane surface to selective image tumor cells. The distribution (B) and expression (C and D) of NCL in breast cancer MDA-MB-231, MCF-7 cells and human normal MCF-10A cells. The localization (E and F) of AS411@RuPEP nanoprobe in breast cancer MDA-MB-231, MCF-7 cells and human normal MCF-10A cells. G LSCM images on co-cultivation of MDA-MB-231 and MCF-10A cells in one confocal dish after incubation with 0.2 mL AS1411@RuPEP (5 μM) for 6 h. Scale bar = 20 μm. G The overlay data were analyzed using Image Pro Plus
Fig. 4Specific-targeted NIR fluorescence tumor imaging intransgenic MMTV-PyMT primacy breast cancer mice. A The arrows show the tumor sites. Time-dependent in vivo NIR fluorescence images of transgenic MMTV-PyMT primacy breast cancer mice after tail intravenous injection of 20 μM, 100 μL, AS1411@RuPEP. (Excited by 475 nm, emission at 680 nm). B Fluorescence intensity of AS1411@RuPEP in mice tumor area and non-tumor area is quantitatively determined. C Fluorescence intensity of AS1411@RuPEP (average cps) in dissected organs or tissues is quantitatively determined. Data are presented as the mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001. D Tissue distribution and drug metabolism of AS1411@RuPEP at 24, 72 and 108 h. E Histochemistry analysis of heart, liver, spleen, lung, kidney and brain section stained with hematoxylin eosin of transgenic MMTV-PyMT primacy breast cancer mice at 108 h after i.v. administration of saline and 20 μM. Bar: 50 μm
Fig. 5Distinguish and detect tumor area in human breast cancer patient section for nanoprobe. A Histochemistry analysis of human breast cancer tissues section stained with hematoxylin eosin of five specimens of invasive ductal carcinoma patients. B The targeting imaging of nanoprobe (5 μM) to distinguish cancerous area and paracancerous area in the frozen sections (OCT-embedded) of the fresh human invasive ductal carcinoma tissues observed by fluorescence microscope. C CLSM enlarged observation of the distribution of nucleolin and nanoprobe in cancerous area and paracancerous area. The whole tissues were stained by DAPI in blue, NCL stained in Green and Nanoprobe is red. D The merge curve of three channels emission intensity for cancerous and paracancerous cells analyzed by using Image-Pro Plus softwire. E The NCL protein expression of cancerous and paracancerous tissues in five specimens of invasive ductal carcinoma patients (n = 5). F Quantitative analysis of NCL expression and tumor grade of five specimens of invasive ductal carcinoma specimens (n = 5). Note: The fresh human cancer tissues were The data are presented as the means ± SDs of three independent experiments. *P < 0.05,** P < 0.01 and ns—not significant
Fig. 6The effectiveness of nanoprobe to distinguish different grades of invasive ductal carcinoma. A The operation procedure flow diagram for the nanoprobe to detect tumor tissue specimens. B The pathological characteristics of normal and grade I-III tissues of invasive ductal carcinoma specimens by HE staining. Each group of ten specimens. C The imaging of nanoprobe (5 μM) for normal and different tumor grade specimens. The paraffin sections were stained with DAPI (blue) and nanoprobe (red). Scale bar: 200 μm (D) The emission intensity curve of nanoprobe in different specimens at the trace of white mark line. E The statistical analysis of the average intensity of equal area in normal different tumor grade specimens of each group of 10 cases and three repetitions respectively. n = 10 *P < 0.05,** P < 0.01 and ns—not significant